About: Pulse immunosuppressive therapy for multiple sclerosis during the SARS-CoV-2 lockdown de-escalation plan: safety algorithm

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pulse immunosuppressive therapy for multiple sclerosis during the SARS-CoV-2 lockdown de-escalation plan: safety algorithm Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Pulse immunosuppressive therapy for multiple sclerosis during the SARS-CoV-2 lockdown de-escalation plan: safety algorithm
Creator	Asuncion, Maria Bendicho, Iborra Carreón-Guarnizo, Carreón-Guarnizo, Ester Coautores, Ester Es, Amoralesortiz@yahoo Es, Asunib@yahoo Eustasio Meca-Lallana, Jose Hernández-Clares, Rocio Iborra-Bendicho, Maria Iniesta-Martínez, Francisca Jiménez-Veiga, Judith Morales-Ortiz, Ana Moreno Docon, Antonio Moreno-Docon, Antonio Valero-López, Gabriel Veiga, Judith
Source	Elsevier; PMC
abstract	Abstract Introduction The COVID-19 pandemic is changing approaches to diagnosis, treatment, and care provision in multiple sclerosis (MS). During both the initial and peak phases of the epidemic, the administration of disease-modifying drugs, typically immunosuppressants administered in pulses, was suspended due to the uncertainty about their impact on SARS-CoV-2 infection, mainly in contagious asymptomatic/presymptomatic patients. The purpose of this study is to present a safety algorithm enabling patients to resume pulse immunosuppressive therapy (PIT) during the easing of lockdown measures. Methods We developed a safety algorithm based on our clinical experience with MS and the available published evidence; the algorithm assists in the detection of contagious asymptomatic/presymptomatic cases and of patients with mild symptoms of SARS-CoV-2 infection with a view to withdrawing PIT in these patients and preventing new infections at day hospitals. Results We developed a clinical/microbiological screening algorithm consisting of a symptom checklist, applied during a teleconsultation 48 h before the scheduled session of PIT, and PCR testing for SARS-CoV-2 in nasopharyngeal exudate 24 h before the procedure. Conclusion The application of our safety algorithm presents a favourable risk-benefit ratio despite the fact that the actual proportion of asymptomatic and presymptomatic individuals is unknown. Systematic PCR testing, which provides the highest sensitivity for detecting presymptomatic cases, combined with early detection of symptoms of SARS-CoV-2 infection may reduce infections and improve detection of high-risk patients before they receive PIT.
has issue date	2020-07-04(xsd:dateTime)
bibo:doi	10.1016/j.nrleng.2020.06.001
has license	els-covid
sha1sum (hex)	b918df5db6480fd27c62400155302c777987c813
schema:url	https://doi.org/10.1016/j.nrleng.2020.06.001
resource representing a document's title	Pulse immunosuppressive therapy for multiple sclerosis during the SARS-CoV-2 lockdown de-escalation plan: safety algorithm
has PubMed Central identifier	PMC7334962
resource representing a document's body	covid:b918df5db6480fd27c62400155302c777987c813#body_text
is schema:about of	named entity 'plan' named entity 'AUTOR' named entity 'safety' named entity 'safety' named entity 'Title' named entity 'multiple sclerosis' named entity 'plan' named entity 'epidemia' named entity 'de-escalation' named entity 'lockdown' named entity 'algorithm' named entity 'multiple sclerosis' named entity 'SARS-CoV-2' named entity 'epidemia' named entity 'immunosuppressive therapy' named entity 'algorithm' named entity 'lockdown' named entity 'immunosuppressive therapy' named entity 'de-escalation' named entity 'lockdown' named entity 'immunosuppressive therapy' named entity 'SARS' named entity 'yahoo' named entity 'SARS-CoV-2' named entity 'asymptomatic' named entity 'PPMS' named entity 'immunosuppressed' named entity 'sensitivity and specificity' named entity 'SARS-CoV-2' named entity 'high-risk' named entity 'infection' named entity 'infection' named entity 'immunosuppressed' named entity 'Objective 1' named entity 'SARS-CoV-2' named entity 'infection' named entity 'IgM' named entity 'outpatient' named entity 'Spain' named entity 'diagnostic tests' named entity 'infection' named entity 'infection' named entity 'high-risk' named entity 'epidemiological' named entity 'primary progressive multiple sclerosis' named entity 'asymptomatic' named entity 'Multiple sclerosis' named entity 'COVID-19 pandemic' named entity 'triage' named entity 'asymptomatic' named entity 'healthcare staff' named entity 'asymptomatic' named entity 'serology tests' named entity 'COVID-19 pandemic' named entity 'infection' named entity 'infection' named entity 'infection' named entity 'SARS-CoV-2' named entity 'infection' named entity 'healthcare systems' named entity 'diagnostic tests' named entity 'infection' named entity 'PCR' named entity 'asymptomatic' named entity 'day hospital' named entity 'SARS-CoV-2' named entity 'infection' named entity 'general population'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software